We have synthesized and characterized nearly monodisperse and highly pure gold nanoparticles (2 and 5 nm) coated with non-immunoactive mono-and disaccharides, modelled after the capsular polysaccharide of serogroup A of the Neisseria meningitidis bacterium. We have used them to test their ability to induce immune cell responses as a consequence of their multivalency. The results indicate that they are indeed immunoactive and that immunoactivity is strongly dependent on size, and larger, 5 nm nanoparticles perform far better than smaller, 2 nm ones. Immune response (activation of macrophages) initiates with the whole nanoparticle recognition by the surface of antigen-presenting cells, independent of the saccharide oligomerization (or charge) on the nanoparticle surface. The induction of T cell proliferation and the increase of IL-2 levels, a consequence of the expression of MHC II involved in antigen presentation, require the presence of a disaccharide on the nanoparticle, not just a monosaccharide. A possible explanation is that, at this stage, the saccharides are detached from the gold surface. These results may provide leads for designing new saccharide-based, nanoparticle-conjugate vaccines.
Introduction
Monolayer-protected gold nanoparticles (Au-NPs) share with several nanosystems (liposomes, dendrimers, for instance) the property of multivalency 1,2 since they present a collection of functional groups on their periphery. It is a widely accepted paradigm that multivalent systems show enhanced binding ability against multivalent counterparts.
1,3 This is the case for systems governing cell-cell, protein-protein, and protein-cell interactions, for instance. 4 Multivalency of Au-NPs has been exploited for many applications 5, 6 spanning, inter alia, enzyme mimicry, 7-9 protein sensing and recognition, [10] [11] [12] and gene regulation. 13 For drug or gene delivery, the ability to release their payload, once internalized into cells, 14, 15 in a process mediated by cytoplasmic thiol compounds is an advantage of Au-NPs over other polymeric nanosystems where the cargo is covalently, and hence very strongly, bound to the polymer. One of the major problems related to the use of Au-NPs for biomedical applications is the fact that immune cells in the bloodstream and in tissues have the ability to entrap and eliminate Au-NPs. [16] [17] [18] [19] A nanoparticle's interaction with plasma proteins (opsonins) and blood components (via hemolysis, thrombogenicity and complement activation) may inuence uptake and clearance and hence potentially affect distribution and delivery to the intended target sites. The conventional way to overcome this problem is to make Au-NPs stealthy to the immune system, typically by functionalization on their surface with polyethers.
20,21
In addition to their primary role in pathogen clearance, blood components like the complement system also promote humoral and cell-mediated immunity. Local activation of complement by nanoparticles administered via subcutaneous and intradermal routes may indeed benet vaccine efficacy. In this paper we address the question of the interaction of saccharide-functionalized Au-NPs in vitro with blood components like monocytes with the aim to evidence their ability to induce immune responses and the factors (size, saccharide oligomerization) inuencing it. Successful systems may nd applications as synthetic vaccines. The design of new vaccines requires the mimicry of key pathogen features like size, shape and surface molecule organization without, of course, the ability to cause diseases. 22 For these reasons nanosystems like dendrimers and polymers have been used for this purpose. Properly functionalized gold nanoparticles 23, 24 appear to be suitable choices for antigens because antigen processing is facilitated if antigens are particulate and have a repetitive surface organization, which increases phagocytosis and the ability, as said above, to activate complement and recruit other molecules of the innate humoral immune system. Peptidefunctionalized Au-NPs have shown the ability to enhance immune responses in cells, 25, 26 and gold nanoparticles bearing tumor-associated glycopeptide antigens have recently been reported as promising potential cancer vaccines. 27 We have recently shown 28 that Au-NPs functionalized with oligosaccharides (Glyco-Au-NPs) designed to mimic the polysaccharide capsule that coats serogroup A of the Neisseria meningitidis bacterium 29 (MenA) bind very strongly to polyclonal human antibodies against MenA. At the same nominal concentration of saccharides the nanoparticles showed a more than three orders of magnitude higher binding affinity than their counterparts not bound to the gold cluster: a remarkable result, fully consistent with the multivalent nature of the system. Our data showed also that the strength of the interaction with the antibodies was not dependent on the oligomerization of the saccharide used for the passivation of the gold cluster as mono-, di-and tri-saccharide-functionalized Au-NPs performed quite similarly. In contrast, the affinity constants of nanoparticle-unbound saccharides were oligomerizationdependent with the trisaccharide performing best. This suggests that the antibody when interacting with the Au-NPs can hardly differentiate a surface made up by a mono-, di-or trisaccharide. Synthetically this is quite relevant because a monosaccharide is much more accessible than an oligomer, even short as a trisaccharide.
A complex cascade of events is required for inducing immune responses. These events include adaptive events that take place on the surface of antigen-presenting cells (APCs), which display foreign antigens coupled with MHC to a T cell receptor complex for effective T cell priming and B/T cell activation. APCs collaborate also with the innate system by cytokines, which steers the differentiation of T helper (Th) cells into Th1 or Th2 subsets. 30 Accordingly, in addressing the ability of our Glyco-Au-NPs to elicit immune cell responses, we have evaluated: (a) the activation of APCs; (b) the induction of effector functions in the same cells; and (c) the ability to stimulate T cells. The role of the size and of the oligomerization of the saccharide present on the surface of the nanoparticles in the different processes studied has been addressed by considering Glyco-Au-NPs of two different sizes (2 and 5 nm core diameter) passivated with thiols functionalized with a mono-and a disaccharide. Liposome-, polymer-or dendrimer-based vaccines are typically of a size of at least 10 nm. 22 We used Glyco-Au-NPs with a maximum overall diameter of ca. 9 nm corresponding to a gold core of 5 nm because a 5.5 nm diameter of the gold core is considered as the threshold limit to allow renal clearance in gold-based nanoparticles 31 and, hence, to avoid accumulation of the metal in the organism: a critical issue for possible in vivo applications. Thus our size limit was the result of considering both renal clearance and maximization of APC interactions for possible future vaccine development. In spite of the fact that the two sizes studied are not much different, the results indicate that the behavior of the Glyco-Au-NP is quite diverse. Our selected pathogen has been the Neisseria meningitidis bacterium to compare our results with the previous ones 28 concerning polyclonal antibody affinities but also for the high relevance of this bacterium that causes the highest incidence of epidemics in Saharan and sub-Saharan countries of Africa (the so-called "African meningitis belt"). 32 Furthermore, bacterial meningitis remains a global problem worldwide, accounting for an estimated annual number of 1.2 million cases with at least 5-10% case fatality in industrialized countries and 20% in the developing world. 33 It is thus not surprising that the scientic interest in new approaches for effective vaccine development remains very high.
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Results and discussion
Synthesis and characterization of Au nanoparticles
We have prepared following our protocol, 37 which is a modi-cation adapted for water-soluble Au-NPs of the two-phase Brust synthesis 38 ( Fig. 1 ), 2 and 5 nm nanoparticles ‡ functionalized with monomeric and dimeric saccharides 29 (Glyco-Au-NP 1-2 and 3-4, respectively). Since incorporation of a triethylenglycol (TEG) unit in the monolayer provides to Au-NPs water solubility, prevents nanoparticle aggregation that occurs at the ionic strength of the experiments with cells, and non-specic interactions with biomolecules, 20 TEG-Au-NPs 5 and 6 were used as Au-NP controls in all experiments, while saccharides 8 and 9 were used as monovalent comparison molecules. Glyco-Au-NP 7 is equivalent to Glyco-Au-NP 4 as for dimension and saccharide composition. It differs from 4 for the presence of 5% of uo-rescein as a uorescent tag and was prepared to monitor cell internalization of the nanoparticles. In disaccharide 9 and that present in gold nanoparticles 3 and 4, the native phosphodiester bridge connecting the glycosidic units of MenA has been substituted with a phosphonate 29 as a hydrolytically more stable moiety to prevent early degradation with loss of the Glyco-Au-NPs properties. The Au-NPs were analyzed, for their size, by transmission electron microscopy (TEM) and dynamic light scattering (DLS) (see Table 1 for relevant physical properties) and, for the purity of the monolayer, by 1 H-NMR and thermogravimetry (see ESI †). While TEM provides the size of the gold core, DLS gives the hydrodynamic diameter of the nanoparticle (gold core and surrounding monolayer). DLS is particularly sensitive to the presence of aggregated nanoparticles because of the strong increase of scattered intensity with size. All our samples showed no evidence of aggregation, thus suggesting that the passivation with the saccharides makes them very soluble and not prone to interacting reciprocally. The thiol/particle ratio that gives information on the multivalency of the Glyco-Au-NPs has been obtained from the thermogravimetric analysis and size data as reported. 41 Glyco-Au-NPs with a monolayer composed of a monosaccharide (1 and 2) are neutral, while those composed of a disaccharide (3 and 4) are anionic, as proven by the respective Z potentials (Table 1) . ‡ For the sake of clarity we refer to the gold core to identify the size of the nanoparticles throughout the paper.
Macrophage activation
Preliminarily, we ruled out the possibility that immune cell responses were due to the presence of endotoxin contaminations, such as lypopolysaccharide (LPS), introduced into the system through chemicals, materials, or equipment. Limulus amebocyte lysate endochrome assays were performed in four different batches of each compound and the concentration of LPS was measured. LPS concentrations were always below the value of 0.01 ng ml À1 , sufficient to stimulate immune cell responses, 42 suggesting that the compounds under testing were LPS-free and biologically evaluable (data not shown). In addition, to exclude the possibility that the compounds are cytotoxic, cell viability was evaluated by a Trypan blue exclusion test aer 24 h cell exposure to each compound. All compounds showed no toxicity at all concentrations tested (data not shown).
Macrophages are potent immune cells that provide an immediate response against pathogens and may act as APCs to activate adaptive immune responses. Exposure to pathogens can induce a rapid activation of macrophages, which stop proliferation and acquire effector cell functions. 43 We, thus, analyzed in vitro the effects of nanoparticles 1-6 and saccharides 8 and 9 on macrophage proliferation using RAW 264.7 cells, a widely used cellular model that accurately replicates APC biology, such as antigen uptake, processing, and presentation. 44 Cells were rendered quiescent prior to each assay by 18 h serum deprivation. Aer 24 h exposure to increasing concentrations (1 Â 10 À2 to 1 Â 10 2 mM) § of each compound, cell proliferation was signicantly inhibited (À55 AE 1% over compound-untreated cells as controls) only by 5 nm Glyco-Au-NPs 2 and 4 at a 1 Â 10 2 mM concentration ( Fig. 2 ). To demonstrate that the inhibition of macrophage proliferation is specic and not related to a reduction in cell viability, the Trypan blue exclusion test was performed at the end of cell exposure to each compound. The results indicate that the observed decrease in cell proliferation is not due to cytotoxicity as cell viability remains >95%. Apoptosis and necrosis were also analyzed under epiuorescence microscopy in cells treated with 1 Â 10 2 mM Glyco-Au-NPs 1-4 for 24 h. Cells treated with the non-conjugated saccharides 8 and 9 or the TEG-functionalized Au-NPs 5 and 6 devoid of the saccharides were used as a comparison. Actinomicyn D, a cytotoxic inducer of apoptosis,
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was used as a positive control. None of the tested Glyco-Au-NPs signicantly affected cell death, indicating that the inhibition of cell proliferation occurs through a specic blockage of the cell cycle progression (ESI, Fig. S6 †) . This result suggests that the conjugation to Au-NPs confers to the saccharides the ability to activate macrophages and that this property is dependent on the Au-NP size, with 5 nm nanoparticles giving comparable results to those obtained when the polysaccharide bacterium capsule (MenA) is used as a 
a Diameter of the gold core. b Hydrodynamic diameter of the entire nanoparticle.
c Mean value estimated from the thermogravimetric analysis and the size of the gold core (see ref. 39 for details). § The concentrations indicated in the case of the nanoparticles refer to the organic component. The Au-NP concentration can be derived by dividing these numbers by the number of ligands present on the monolayer as reported in Table 1 .
natural antigen. Moreover, there is little difference in the activity of 5 nm Glyco-Au-NPs, regardless of whether they are functionalized with a monomeric or a dimeric saccharide (compare 2 vs. 4). Thus, macrophage activation is dependent on size, but very little on oligomerization (or charge) of the saccharide on the Au-NP surface.
Since the blockage of macrophage cycle progression correlates with a cell phenotype differentiation from macrophage-to dendritic-like cells, we then studied the effects of the nanoparticles on RAW 264.7 cell morphology. As shown in Fig. 3 , native cells (CTRL) had a macrophage-like morphology with small nuclei and nely granulated cytoplasm. Cells appeared elongated with two short cytoplasmic processes. A morphological transformation of RAW 264.7 cells from macrophage-like cells into dendritic-like cells was clearly observed aer cell treatment with Glyco-Au-NPs (1 Â 10 2 mM). Dendritic morphology was characterized by multiple prominent cytoplasmic processes.
Glyco-Au-NP-treated cells acquired larger nuclei, prominent nucleoli, and increased cytoplasmic granularities. This morphological transformation is particularly evident in cells treated with 5 nm Glyco-Au-NPs, as the percentage of dendriticlike cells was almost twice that observed with the smaller (2 nm) Glyco-Au-NPs (Table 2) . At the same concentration (1 Â 10 2 mM) Glyco-Au-NPs elicited similar responses to that observed with MenA. No signicant effects were observed in the cells treated either with the nonconjugated saccharides 8 and 9 or the TEG-functionalized AuNPs 5 and 6. This result indicates that the functionalization, and not just the Au-NPs per se, is at the origin of the observed effects. The blockage of macrophage proliferation, together with the acquisition of a dendritic-like phenotype, clearly indicates that the Glyco-Au-NPs are immunoactive.
The next step was to investigate whether Glyco-Au-NPs activate effector functions in the same cells. Fig. 4 and 5 show the effects induced by each compound on the production of typical pro-inammatory mediators (e.g. ROS and TNF-a). The data demonstrate that, aer processing Glyco-Au-NPs 1-4 as antigenic molecules, macrophages become active APCs (although to different extents) that attract responder cells to the site of the inammation and start adaptive immune cell responses.
The membrane expression of class II major histocompatibility complex molecules (MHC II), which represents the rst marker of a mature APC, was then examined by ow cytometry in RAW 264.7 cells treated with the different systems (1 Â 10 2 mM). No change in the expression levels of MHC II was observed in cells treated with non-conjugated saccharides 8 and 9 or TEG-functionalized Au-NPs 5 and 6, while a 3-and a 6-fold increase in the MHC II expression was measured in cells treated with 2 or 5 nm Glyco-Au-NPs, respectively (Table 2 and Fig. S7 †) . It is noteworthy that 5 nm Glyco-Au-NPs exert identical (or even larger) MHC II expression levels to MenA CPS. Once again, nanoparticles are differentiated by their size and not by the presence of a monomeric or dimeric saccharide (or charge) on their surface. Cellular uptake of 5 nm Glyco-Au-NPs 7 by RAW 264.7 cells was next determined by immunouorescence and confocal microscopy analysis. As shown in Fig. 6 , uorescein-functionalized Glyco-Au-NPs 7 are internalized (green signal) by APC with no absorption onto the cell surface (red signal). The overall data conrm that the Glyco-Au-NPs enter the cells and start expressing molecules (MHC II) involved in antigen presentation.
Glyco-Au-NPs induce T cell responses
To better explore the potentiality of these Glyco-Au-NPs as leads for new vaccine design, their ability to induce T cell responses was determined in human homologous monocytes/T cell cocultures. 40 The generated T cell responses are essential for developing a functional T cell memory following vaccination. Thus, human monocytes were treated with increasing concentrations (1 Â 10 À2 to 1 Â 10 2 mM) of each compound, and, aer six days of cell co-cultures, T cell proliferation ( Fig. 7 and S8 †) and IL-2 levels (Table 3 and Fig. S9 †) were determined. Nonconjugated saccharides 8 and 9, TEG-functionalized Au-NPs 5 and 6, as well as Glyco-Au-NPs 1 and 2 (i.e. the nanoparticles functionalized with the monosaccharide), failed to induce signicant T cell proliferation at all concentrations tested, while both Glyco-Au-NPs 3 and 4 were effective. Glyco-Au-NP 4 was more potent than 3; its maximal effect was a 13-fold increase at 1 Â 10 1 mM in comparison with controls (native cells). Consistently, the IL-2 levels in the cell culture medium (Table 3 ) signicantly increased aer Glyco-Au-NP 4 cell treatment (almost a 12-fold increase at 1 Â 10 1 mM vs. controls).
The overall data clearly demonstrate that Glyco-Au-NPs 4 are the most effective nanosystems in activating T cell responses. The picture that emerges from our results is the following (see Fig. 8a ): (i) Glyco-Au-NPs activate macrophages leading to the blockage of their cycle progression and inducing their differentiation into dendritic-like cells; (ii) they induce on macrophages the expression of MHC II involved in antigen presentation to T lymphocytes; (iii) following their internalization and degradation, the constituent saccharides are loaded onto MHC II and are transported to the APC surface for presentation; (iv) 5 nm Glyco-Au-NPs, functionalized with disaccharide, signicantly induce T cell proliferation and IL-2 release. Processes (i) and (ii) require intact nanoparticles taking advantage of their multivalency and proceed via Glyco-Au-NPs surface recognition. Processes (iii) and (iv) involve very likely Glyco-Au-NP degradation into APCs, a process that implies chemical modications of the nanoparticles.
As in the case of the interaction with the antibodies, 28 the efficiency of the nanosystems is dependent on their size (5 nm are better than 2 nm) but very little on the oligomerization (and charge) of the saccharide on the surface (the effect is very similar for mono-and di-saccharide-functionalized nanoparticles, which are neutral and anionic, respectively), see Fig. 8b . The occurrence of a surface-recognition process controlling steps (i) and (ii) requires a packed surface, a situation more easily obtained with a less curved surface such as that of the larger, 5 nm, nanoparticles as compared to the smaller, 2 nm, ones. It is interesting to point out that, in contrast, when a substrate needs to penetrate into the organic monolayer, the opposite situation occurs, i.e. smaller Au-NPs perform better than larger ones, as we have recently shown.
46 Processes (iii) and (iv) require nanoparticle degradation and, consistently, disaccharide-functionalized nanoparticles are required in this case, see Fig. 8c . Likely, within the cell, the saccharide-functionalized thiols are detached from the surface and, at this stage, being monomeric or dimeric becomes relevant for T cell activation. It has been shown that the (PHA), a widely used mitogen able to trigger cell division in T-lymphocytes, were considered as positive controls, while TEG-functionalized Au-NPs 5 and 6 were used as Au-NPs controls, and compound-untreated cells (CTRL) as negative controls. *P < 0.05; **P < 0.01 vs. CTRL.
thiolic units can be displaced from the gold surface by glutathione. 15, 47 This mode of release utilizes the dramatic differential between extra-and intracellular glutathione levels. It is possible that this is what happens in this case, too. This is supported by the increased uorescence intensity of internalized nanoparticles 7 (see Fig. 6 ), reasonably a consequence of the release of the uorophore from the Au-NP surface.
14 The uorescence intensity of uorescein when bound to the gold surface is very small due to its quenching 14 by the gold nanoparticle core while it increases when released into the solution. In any case, T cells appear to recognize dimeric, but not monomeric saccharidefunctionalized gold nanoparticles: whether this is due to differences in their intracellular processing, as we suggest, or antigenic determinants is a matter of plausible speculation and this point should be claried in future work.
Conclusions
In conclusion, we have demonstrated that the conjugation of small size, fully synthetic, non-immunogenic saccharides to AuNPs confers upon them the ability to induce immune cell responses. The importance of multivalency to increase the selectivity and the strength of binding but also to induce the immunoactivity is clearly evidenced by the ineffectiveness of non-conjugated saccharides, which bind to MenA antibodies but are not immunoactive. Our data show how a complex interplay of features is required with saccharide-functionalized gold nanoparticles for eliciting the complex cascade of events that induce immune responses which eventually may result in immunization. On one hand, for maximizing the cell interaction, size is a key requisite, in full agreement with the reported observation that large size nanoparticles perform better in interacting with cell surfaces 48 and mediating cell responses. 49 On the other hand, for T cell-mediated responses a structured saccharide (in our case a disaccharide) is required. A plausible explanation is that, at this stage, the nanosystem has been in part degraded and the covering functional thiols have been detached from the gold core for presentation by MHC II. The need to comply with both requisites makes 5 nm Glyco-AuNPs 4 functionalized with a disaccharide the best of the studied nanosystems for inducing immune responses in cells.
The present results may provide signicant leads for the design of nanoparticles for developing nanoparticle-based vaccines. The next obvious step will be to test Glyco-Au-NPs in vivo to determine their ability to induce immunization, 22 a feasible development in view of the claimed non-toxicity of gold nanoparticles of the size discussed here.
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Experimental section
Synthesis of the saccharides
Synthesis of the non-conjugated saccharides 8 and 9. The nonconjugated saccharides 8 and 9 were synthesized from their corresponding 1-O-aminopropyl glycoside precursors as follows.
Monosaccharide 8: the aminopropyl glycoside (29 mg, 0.104 mmol) was dissolved in dry pyridine (1.0 ml) under Ar atmosphere, and acetic anhydride (0.1 ml, 1.05 mmol); thereaer, a catalytic amount of N,N-dimethylamino pyridine was added. The reaction mixture was stirred at room temperature for 3 h, and then concentrated in vacuum. The crude residue was dissolved in dry MeOH (3.0 ml) under Ar atmosphere, and then a 0.1 M solution of MeONa in dry MeOH (0.2 ml) was added dropwise. The reaction mixture was stirred at room temperature for 1 h, then neutralised with Dowex 50W X8 resin (H + form), ltered, and concentrated in vacuum. Flash chromatography (CHCl 3 /MeOH 8/2) afforded compound 8 (26 mg, 78%).
Disaccharide 9: the aminopropyl glycoside (20 mg, 0.034 mmol) was treated with acetic anhydride (0.038 ml, 0.34 mmol) and N,N-dimethylamino pyridine, as described for 8. The crude residue was puried by ash chromatography (CHCl 3 / MeOH from 9/1 to 7/3) providing the fully O-and N-acetylated derivative (22 mg, 77%). This compound was dissolved in dry MeOH (1.0 ml) under Ar atmosphere, and then a 0.1 M solution of MeONa in dry MeOH (0.026 ml) was added. Aer stirring at room temperature for 3 h, the reaction mixture was neutralised with aq. HCl 5% and the solution concentrated in vacuum. The residue was dissolved in H 2 O, rst eluted through a column lled with Dowex 50W X8 resin (H + form), and then through a column lled with the same resin in Na + form. The eluate was lyophilized to afford 9 (15 mg, 91%).
Nanoparticle synthesis
The monomeric and dimeric saccharides used for nanoparticle passivation as well as Glyco-Au-NPs 1-4 were synthesized as previously described. 27, 28 The triethyleneglycol (TEG)-functionalized Au-NPs (TEG-Au-NPs) 5 and 6 were synthesized as reported.
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Fluorescein-tagged GlycoNPs 7: the nanoparticles used for cell internalization studies were prepared following the same procedure, but using a mixture of two thiols, the disaccharide-functionalized thiol and the uorescein-tagged thiol. The scheme for the preparation of the Fluorescein-tagged thiol (iv, see ESI) is reported in the ESI. † To a solution of TOABr (94 mg, 0.171 mmol) in 68 ml toluene, an aqueous solution of HAuCl 4 $H 2 O (27 mg, 0.0685 mmol) in 1.0 ml Milli-Q water was added and shaken vigorously until the aqueous layer became transparent. The reddish-orange organic layer was carefully separated from the aqueous solution and transferred in a ask with a magnetic bar. Dioctylamine (21 mg, 0.0856 mmol) was added into the solution under vigorous stirring at room temperature for 3 h. A solution of NaBH 4 (26 mg, 0.685 mmol) in 1.0 ml Milli-Q H 2 O was added drop by drop to the organic layer under vigorous stirring (1 h). The color of the solution immediately changed to purple. The organic layer was again carefully separated and transferred into a ask with a magnetic bar. The freshly prepared mixture of disaccharide-functionalized thiol (12 mg, 0.0162 mmol) and iv (0.70 mg, 0.0010 mmol) in DMF (1 ml) was added and allowed to stir until the toluene layer became colorless. A red precipitate was obtained aer centrifugation followed by decantation of the organic layer. Aer washing with Et 2 O (3 Â 30 ml) and EtOAc (2 Â 30 ml) the solid residue was dissolved with the minimum amount of water. On slow addition of THF a red material precipitated from the aqueous layer and the precipitate was collected aer centrifugation followed by removal of solvents. The same procedure was repeated to afford pure 7 (17 mg).
Nanoparticle characterization
TEM images were recorded on a copper grid using a Jeol 300PX instrument. TGA analyses were recorded by exploring a 30-800 C interval using a temperature ramp of 20 C min À1 under nitrogen using a SDT 2960 model TA instrument. Dynamic light scattering (DLS) and Z potential measurements were carried out with a Malvern Zetasizer Nano S instrument thermostatted at 25 C, using 0.1 mg ml À1 solutions of nanoparticles in water. NMR spectra were recorded on a Bruker AC-300 or AC-250 spectrometer. Diffusion-ordered 1 H NMR spectra were recorded using the low eddy currents distortion bipolar gradients (LEDbp) sequence, which allows differentiation of molecules based on their diffusion coefficients. This provides not only an unequivocal conr-mation that the thiols are bound to the Au-NPs surface, but also a way to assess the purity of the samples. Further determinations of the organic content of each preparation were performed both by TGA and by analyzing the soluble material using or Glyco-Au-NPs 1-6 were tested, they were added to each well just before the addition of the reference serum. The plates were then incubated with alkaline phosphatase-conjugate antimouse, stained with p-nitrophenyl phosphate, and the absorbance was measured at 405 nm with an Ultramark microplate reader. Experiments were repeated in triplicate. Control experiments to verify unspecic binding were performed by coating the ELISA plates with colominic acid from Escherichia coli.
Cell cultures
The mouse monocyte/macrophage cell line RAW 264.7 was cultured in high glucose Dulbecco's Modied Eagle's Medium (DMEM) supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin in a 37 C incubator with 5% CO 2 . Cells were grown in 75 cm 2 asks and sub-cultured by scraping when they reached 90% conuence with a 1 : 5 or 1 : 10 ratio in fresh medium. Peripheral blood mononuclear cells (PBMC) were isolated by gradient centrifugation onto Ficoll-Hystopaque of venous blood obtained from healthy volunteers aer their informed consent. 37 PBMC were suspended in RPMI-1640 medium containing 10% heat inactivated FBS, 100 mg ml À1 kanamycin, 1 mM sodium pyruvate, 2 mM L-glutamine, 1% MEM amino acid solution and 0.01 mM 2-mercaptoethanol for immediate use. Human monocytes were isolated from heparinised venous blood of healthy volunteers, and their purity was assessed with the pan-leukocyte anti-CD45 (HLE-1) and the anti-CD14 (Leu-M3) monoclonal Abs, as previously described. 37 Cells were used on the day of isolation under endotoxin-free conditions. Before each experiment, the viable cell count was assessed (always >95%) by Trypan blue staining and cells were seeded, in complete fresh medium, at different densities 24 h prior to compound treatments. Compound-untreated cells were considered as negative controls, while cells treated with Men-A (1 Â 10 2 mg ml À1 ) were considered as positive controls. Monocytes and PBMC used for co-culture experiments were always isolated from the same healthy donor.
Cell proliferation
Proliferation was analyzed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, as previously described. 38 Briey, RAW 264.7 cells were seeded (0.5 Â 105 cells per well) in 24-well culture plates and treated with increasing concentrations (1 Â 10 À2 to 1 Â 10 2 mM) of compounds 1-8 for 24 h at 37 C in a 5% CO 2 humidied incubator. Absorbance was measured at 570-630 nm using an Ultramark microplate reader. The percentage of cell proliferation was calculated as (x Â 100)/y, where x and y are the absorbance read in compound-treated and compounduntreated cells, respectively. 
Annexin V and propidium iodide assays
Production of reactive oxygen species
Intracellular reactive oxygen species production was measured by incubating the cells with the uorescent probe 2 0 ,7 0 -dichlorodihydrouorescein diacetate (DCFH-DA), as previously described. 54 RAW 264.7 cells were seeded (0.5 Â 10 5 cells per well) in 24-well plates and treated with increasing concentrations (10 À2 to 10 2 mM) of each compound for 1 h. Accumulation of dichlorouorescein was measured as an increase in the uorescence at 525 nm, when the samples were excited at 488 nm using a microplate spectrouorometer.
Production of TNF-a
Compounds were tested for their effects on the production of pro-inammatory mediators, such as tumor necrosis factor (TNF)-a, as previously described. 54 RAW 264.7 cells were seeded at a density of 0.6 Â 10 5 cells per well in 24-well plates and treated with increasing concentrations (10 À2 to 10 2 mM) of each compound for 24 h. At the end of each experiment, supernatants were collected and stored until measurements. The amounts of TNF-a in cell culture medium were assayed using enzyme-linked immunosorbent assay (ELISA). The concentrations of the cytokine in the samples were determined by extrapolation from specic reference standard curves.
Glyco-Au-NP uptake by macrophages
The cellular uptake of 5 nm Glyco-Au-NPs was assessed analyzing intracellular localization of FITC-labeled 5 nm GlycoAu-NPs (14) by confocal scanning laser microscopy. RAW 264.7 cells (1 Â 10 4 cells per well) were allowed to adhere overnight on sterile cover slips in 24-well culture plates and pulsed (3 h) with (1 Â 10 2 mg ml
À1
) FITC-labeled 5 nm Glyco-Au-NPs in complete medium. The cover slips were washed twice with ice-cold PBS and cells xed with paraformaldehyde 3% for 15 min at 4 C.
Aer two additional PBS washings, cell membranes on the cover slips were labelled with ALexa Fluor 647-conjugated anti-mouse CD14 monoclonal Ab at room temperature for 1 h in the dark. Aer one wash with PBS, the cover slips were mounted on glass slides by SlowFadeÒ reagent. Cover slips were maintained in the dark overnight at 4 C and analyzed by a confocal scanning laser microscope (Leica TCS P2). Green uorescence was observed with a 505-550 nm band-pass emission lter under 488 nm laser illumination and red uorescence was observed with a 560 nm long-pass emission lter under 543 nm laser illuminations.
Flow cytometry analysis
The acquisition of effector functions by macrophages was assessed analyzing the levels of major histocompatibility complex class II (MHC II) surface expression. RAW 264.7 cells were seeded (1 Â 10 5 cells per well) in 6-well culture plates and treated with compounds 1-8 (1 Â 10 2 mM) for 24 h at 37 C in a 5% CO 2 humidied incubator. Following incubation, cells were washed once with PBS, resuspended in 100 ml PBS and incubated with Alexa Fluor 647-conjugated anti-mouse I-A/I-E monoclonal Ab for 15 min at room temperature in the dark. Cells were then washed twice with PBS and analyzed by ow cytometry. Emitted uorescence was analyzed by using FACSDiva soware.
T cell activation assays
Monocytes (1 Â 10 5 cells per well), used as APCs, were pulsed with increasing concentrations (1 Â 10 À2 to 1 Â 10 2 mM) of each compound 1-8 for 24 h. Responder PBMC (1 Â 10 6 cells per ml)
were labeled with 0.25 mM carboxyuorescein succinimidyl ester (CFSE) in serum-free PBS for 30 min at 37 C. Filtered FBS was then added to stop the reaction, and cells were washed several times with RPMI-1640. 5 Â 10 4 CFSE-labeled responder T cells were co-cultured with antigen-pulsed or unpulsed homologous monocytes for six days at 37 C, 5% CO 2 in a humidied incubator. Phytohemagglutinin (PHA) (1 mg ml À1 ) was used as a positive control of PBMC proliferation. Aer six days of co-culture, cells were harvested, washed three times with warmed PBS, resuspended in fresh PBS, and analyzed by ow cytometry. Cell proliferation was measured as reduction of CFSE uorescence intensity due to cell division by using FACSDiva soware.
Measurement of IL-2 production
Monocytes (1 Â 10 5 cells per well), used as APCs, were pulsed with increasing concentrations (1 Â 10 À2 to 1 Â 10 2 mM) of compounds 1-8 for 24 h. Responder PBMC (5 Â 10 4 cells per well) were co-cultured with antigen-pulsed or unpulsed homologous monocytes for six days at 37 C, 5% CO 2 in a humidied incubator. PHA (1 mg ml À1 ) was added in positive control wells. Aer six days of co-culture, the supernatants were collected and stored at À20 C until assays. The levels of IL-2
were measured by ELISA using a mouse anti-human IL-2 monoclonal Ab and quantied with a recombinant IL-2 standard. Absorbance was measured at 450 nm using an Ultramark microplate reader, and the concentration of IL-2 in each sample was determined by extrapolation from reference standard curves. The detection limit of this method was 4 pg ml À1 .
Statistical analysis
Results are expressed as means AE SEM of at least ve different experiments run in triplicate. Statistical signicance was evaluated by Student's t-test for unpaired varieties. Differences were considered statistically signicant when p < 0.05. The soware Origin version 6.0 (Microcal Soware) was used as a nonlinear regression model for analysis of the concentration-response data to obtain the 50% inhibitory concentration value (IC50).
